Lonza and Agennix link up for talactoferrin production

Switzerland-based Lonza (SIX: LONN) and Agennix AG (FSE: AGX) of Germany have announced an agreement for the production of the first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC) by Agennix.

Under the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. This agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

“We are committed to supporting emerging therapeutics through clinical trial milestones,” said Stephan Kutzer, chief operating officer at Lonza Custom Manufacturing, adding: “Our partnership with Agennix is an example of this commitment and demonstrates Lonza’s ability to offer access to our development and manufacturing expertise at an early stage of production.”